Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Critical Care | September 03, 2024 | September 03, 2024 |
| Outset Medical, Inc.OM · Entity 7026 | Director | May 31, 2023 | May 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date September 03, 2024 · Filed September 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,287.4373 |
Ending reported balance
After 2024-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-03 · Grant · Acquired 10,910 · Balance 86,817.4373 F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date. Row 2 · 2024-09-03 · Tax withholding · Disposed 5,530 · Balance 81,287.4373 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date.
Outset Medical, Inc.
Report date May 31, 2023 · Filed May 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,596 |
Reported balance
After 2023-05-31 transaction · row 1
1 source rowRow 1 · 2023-05-31 · Grant · Acquired 7,681 · Balance 24,596 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 19, 2025
Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 22,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-19 · Disposition to issuer · Disposed 49,719 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
MASIMO CORP
Report date June 10, 2026 · Filed June 12, 2026
Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Disposition to issuer · Disposed 7,605 · Balance 0 F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Disposition to issuer · Disposed 22,283 · Balance 0 F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Disposition to issuer · Disposed 6,306 · Balance 0 F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-10 · Disposition to issuer · Disposed 39,904 · Balance 0 F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $166.52 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-10 · Disposition to issuer · Disposed 18,617 · Balance 0 F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Performance-Based Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-10 · Disposition to issuer · Disposed 49,243 · Balance 0 F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").
F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33).
F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years.
F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years.
F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years.
F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding.
F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding.
F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:30 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerPerformance-Based Restricted Stock Unit · Derivative | 49,243 | $180.00 | $8,863,740.00 |
DisclosureSEC source: 0001104659-26-073506 · tm2617401-16_4seq1.xml · derivative · entry 6 Szyman Catherine M. · CIK 0001438538 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,243 shares Expires not disclosed F9 · derivative.exercise_price: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. F8 · price: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F1 · derivative.exercise_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F8 · derivative.exercise_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F9 · derivative.exercise_date: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. F1 · derivative.expiration_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F8 · derivative.expiration_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F9 · derivative.expiration_date: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:30 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 18,617 | $13.48 Strike: $166.52 | $250,957.16 |
DisclosureSEC source: 0001104659-26-073506 · tm2617401-16_4seq1.xml · derivative · entry 5 Szyman Catherine M. · CIK 0001438538 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,617 shares Expires not disclosed F7 · price: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. F1 · derivative.exercise_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F7 · derivative.exercise_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. F1 · derivative.expiration_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F7 · derivative.expiration_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:30 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerRestricted Stock Units · Derivative | 39,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-073506 · tm2617401-16_4seq1.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,904 shares Expires not disclosed F6 · derivative.exercise_price: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. F3 · price: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1 · derivative.exercise_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F6 · derivative.exercise_date: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. F1 · derivative.expiration_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.expiration_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F6 · derivative.expiration_date: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:30 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerRestricted Stock Units · Derivative | 6,306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-073506 · tm2617401-16_4seq1.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,306 shares Expires not disclosed F5 · derivative.exercise_price: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. F3 · price: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1 · derivative.exercise_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F5 · derivative.exercise_date: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. F1 · derivative.expiration_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.expiration_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F5 · derivative.expiration_date: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:30 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerRestricted Stock Units · Derivative | 22,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-073506 · tm2617401-16_4seq1.xml · derivative · entry 2 Szyman Catherine M. · CIK 0001438538 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,283 shares Expires not disclosed F4 · derivative.exercise_price: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. F3 · price: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1 · derivative.exercise_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F4 · derivative.exercise_date: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. F1 · derivative.expiration_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.expiration_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F4 · derivative.expiration_date: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:30 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerCommon Stock | 7,605 | $180.00 | $1,368,900.00 |
DisclosureSEC source: 0001104659-26-073506 · tm2617401-16_4seq1.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · price: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration"). Read SEC document |
| March 11, 2026 Filed Mar 16, 2026 21:21 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionRestricted Stock Units · Derivative | 2,101 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000044 · wk-form4_1773696057.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,306 Underlying: Common Stock · 2,101 shares Expires 2035-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F1 · derivative.exercise_date: As previously reported, the reporting person was granted 8,407 restricted stock units (RSUs) on March 11, 2025 and will vest ratably over four years, 25% of which vested on March 11, 2026. Read SEC document |
| March 11, 2026 Filed Mar 16, 2026 21:21 UTC | MASIMO CORP MASI · Entity 39014 | Tax withholdingCommon Stock | 1,069 | $175.47 | $187,577.43 |
DisclosureSEC source: 0000937556-26-000044 · wk-form4_1773696057.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,605 F2 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain RSUs. Read SEC document |
| March 11, 2026 Filed Mar 16, 2026 21:21 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionCommon Stock | 2,101 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000044 · wk-form4_1773696057.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: As previously reported, the reporting person was granted 8,407 restricted stock units (RSUs) on March 11, 2025 and will vest ratably over four years, 25% of which vested on March 11, 2026. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:50 UTC | MASIMO CORP MASI · Entity 39014 | GrantRestricted Stock Units · Derivative | 39,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000023 · wk-form4_1773183003.xml · derivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,904 Underlying: Common Stock · 39,904 shares Expires 2036-03-06 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: This RSU award was granted on March 6, 2026 and will vest ratably over four years, with 25% of the award vesting on each anniversary of the grant date. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:28 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionRestricted Stock Units · Derivative | 11,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000010 · wk-form4_1771021726.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,283 Underlying: Common Stock · 11,141 shares Expires 2035-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: As previously reported, the reporting person was granted 33,424 RSUs on February 12, 2025 and will vest ratably over three years. One-third of the RSUs vested on February 12, 2026, and the remaining RSUs will vest in two equal installments on the second and third anniversaries of the grant date. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:28 UTC | MASIMO CORP MASI · Entity 39014 | Tax withholdingCommon Stock | 4,568 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000010 · wk-form4_1771021726.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,573 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain performance restricted stock units. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:28 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionCommon Stock | 11,141 | $132.96 | $1,481,307.36 |
DisclosureSEC source: 0000937556-26-000010 · wk-form4_1771021726.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2025 Filed Mar 14, 2025 00:20 UTC | MASIMO CORP MASI · Entity 39014 | GrantRestricted Stock Units · Derivative | 8,407 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-25-000049 · wk-form4_1741911626.xml · derivative · entry 2 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,407 Underlying: Common Stock · 8,407 shares Expires 2035-03-11 F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: This RSU award was granted on March 11, 2025 and will vest ratably over four years, with 25% of the award vesting on each anniversary of the grant date. Read SEC document |
| March 11, 2025 Filed Mar 14, 2025 00:20 UTC | MASIMO CORP MASI · Entity 39014 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 18,617 | $0.00 Strike: $166.52 | $0.00 |
DisclosureSEC source: 0000937556-25-000049 · wk-form4_1741911626.xml · derivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,617 Underlying: Common Stock · 18,617 shares Expires 2035-03-11 F1 · derivative.exercise_date: This option was granted on March 11, 2025 and is exercisable as the option vests. The option vests over a five year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 20:20 UTC | Inari Medical, Inc. NARI · Entity 83035 | Disposition to issuerStock Option · Derivative | 49,719 | Not disclosed Strike: $5.73 | Not disclosed |
DisclosureSEC source: 0001127602-25-005758 · form4.xml · derivative · entry 2 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,719 shares Expires not disclosed F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 20:20 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 22,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005758 · form4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2 · shares: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:17 UTC | MASIMO CORP MASI · Entity 39014 | GrantRestricted Stock Units · Derivative | 33,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-25-000018 · wk-form4_1739571460.xml · derivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,424 Underlying: Common Stock · 33,424 shares Expires 2035-02-12 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: This RSU award was granted on February 12, 2025 and will vest ratably over three years, with one-third of the award vesting on each of the first, second, and third anniversaries of the grant date. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 5,530 | $69.96 | $386,878.80 |
DisclosureSEC source: 0001225208-24-008339 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,287.4373 Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 10,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-008339 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,817.4373 F1 · kind: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date. Read SEC document |
| July 07, 2024 Filed Jul 8, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 258 | $92.32 | $23,818.56 |
DisclosureSEC source: 0001225208-24-007361 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,907.4373 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 827 | $86.72 | $71,717.44 |
DisclosureSEC source: 0001225208-24-005985 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,165.4373 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 609 | $85.09 | $51,819.81 |
DisclosureSEC source: 0001225208-24-005882 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,992.4373 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 32,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005882 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,601.4373 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 5,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005706 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,796 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 3,442 | $85.25 | $293,430.50 |
DisclosureSEC source: 0001225208-24-005706 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,576.4373 Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005706 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,018.4373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 03, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 479 | $85.06 | $40,743.74 |
DisclosureSEC source: 0001225208-24-005706 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,222.4373 Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 16:59 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-013478 · form4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,429 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| April 24, 2024 Filed May 31, 2024 16:59 UTC Amendment | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-017134 · form4a.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,429 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 23:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 8,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002856 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,373.571 F1 · shares: These restricted stock units were granted on February 22, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 27,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-002191 · doc4.xml · derivative · entry 6 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 27,000 | $85.62 | $2,311,653.60 |
DisclosureSEC source: 0001225208-24-002191 · doc4.xml · nonDerivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,813.571 F2 · price: This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 27,000 | $36.75 | $992,250.00 |
DisclosureSEC source: 0001225208-24-002191 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,813.571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 20,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-002191 · doc4.xml · derivative · entry 5 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 20,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 20,000 | $86.46 | $1,729,200.00 |
DisclosureSEC source: 0001225208-24-002191 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,813.571 F1 · price: This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 20,000 | $36.75 | $735,000.00 |
DisclosureSEC source: 0001225208-24-002191 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,813.571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 22:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-009461 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 22:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,000 | $72.68 | $363,400.00 |
DisclosureSEC source: 0001225208-23-009461 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,813.571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 22:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,000 | $36.75 | $183,750.00 |
DisclosureSEC source: 0001225208-23-009461 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,813.571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 21:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008819 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 21:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,000 | $76.00 | $380,000.00 |
DisclosureSEC source: 0001225208-23-008819 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,813.571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 21:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,000 | $36.75 | $183,750.00 |
DisclosureSEC source: 0001225208-23-008819 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,813.571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008138 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,000 | $78.64 | $393,185.00 |
DisclosureSEC source: 0001225208-23-008138 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,813.571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $78.44 to $78.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,000 | $36.75 | $183,750.00 |
DisclosureSEC source: 0001225208-23-008138 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,813.571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| July 10, 2023 Filed Jul 10, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-007434 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2023 Filed Jul 10, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,000 | $90.52 | $452,600.00 |
DisclosureSEC source: 0001225208-23-007434 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,813.571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| July 10, 2023 Filed Jul 10, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,000 | $36.75 | $183,750.00 |
DisclosureSEC source: 0001225208-23-007434 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,813.571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| July 07, 2023 Filed Jul 10, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 252 | $90.46 | $22,795.92 |
DisclosureSEC source: 0001225208-23-007434 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,813.571 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.